Effectiveness of particular inhibitors in vivo and in vitro has been shown in double-negative prostate cancer models, and these tumors usually display active FGF receptor and MAPK signaling to avoid the AR pathway, resulting in delayed prostate cancer progression. Here, AR is linked to prostate carcinoma.